These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

84 related items for PubMed ID: 12820341

  • 21. Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid.
    Pectasides D, Nikolaou M, Farmakis D, Kanakis I, Gaglia A, Kountourakis P, Karamanos NK, Economopoulos T, Raptis SA.
    Anticancer Res; 2005; 25(2B):1457-63. PubMed ID: 15865105
    [Abstract] [Full Text] [Related]

  • 22. Breast cancer and neoadjuvant therapy: any predictive marker?
    Vyzula R, Dusek L, Zaloudík J, Demlová R, Klimes D, Selvekerová S.
    Neoplasma; 2004; 51(6):471-80. PubMed ID: 15640958
    [Abstract] [Full Text] [Related]

  • 23. [Evaluation of cancer-induced bone diseases by bone metabolic marker].
    Takahashi S.
    Clin Calcium; 2006 Apr; 16(4):581- 90. PubMed ID: 16582508
    [Abstract] [Full Text] [Related]

  • 24. First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma.
    Tosi P, Zamagni E, Cellini C, Parente R, Cangini D, Tacchetti P, Perrone G, Ceccolini M, Boni P, Tura S, Baccarani M, Cavo M.
    Eur J Haematol; 2006 May; 76(5):399-404. PubMed ID: 16480429
    [Abstract] [Full Text] [Related]

  • 25. Analysis of biochemical bone markers as prognostic factors for survival in patients with hormone-resistant prostate cancer and bone metastases.
    Petrioli R, Rossi S, Caniggia M, Pozzessere D, Messinese S, Sabatino M, Marsili S, Correale P, Salvestrini F, Manganelli A, Francini G.
    Urology; 2004 Feb; 63(2):321-6. PubMed ID: 14972482
    [Abstract] [Full Text] [Related]

  • 26. Biochemical markers for monitoring response to therapy: evidence for higher bone specificity by a novel marker compared with routine markers.
    Leeming DJ, Hegele A, Byrjalsen I, Hofmann R, Qvist P, Karsdal MA, Schrader AJ, Wagner R, Olbert P.
    Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1269-76. PubMed ID: 18483350
    [Abstract] [Full Text] [Related]

  • 27. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
    Delmas PD, Licata AA, Reginster JY, Crans GG, Chen P, Misurski DA, Wagman RB, Mitlak BH.
    Bone; 2006 Aug; 39(2):237-43. PubMed ID: 16563890
    [Abstract] [Full Text] [Related]

  • 28. Metabolic gaps in bone formation may be a novel marker to monitor the osseous metastasis of prostate cancer.
    Koizumi M, Yonese J, Fukui I, Ogata E.
    J Urol; 2002 Apr; 167(4):1863-6. PubMed ID: 11912449
    [Abstract] [Full Text] [Related]

  • 29. Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients.
    Corso A, Arcaini L, Mangiacavalli S, Astori C, Orlandi E, Lorenzi A, Passamonti F, Klersy C, Pascutto C, Canevari-Sciorati A, Lazzarino M.
    Haematologica; 2001 Apr; 86(4):394-8. PubMed ID: 11325645
    [Abstract] [Full Text] [Related]

  • 30. The use of bone markers in a 6-week study to assess the efficacy of oral clodronate in patients with metastatic bone disease.
    Brown JE, McCloskey EV, Dewar JA, Body JJ, Cameron DA, Harnett AN, Ruutu M, Purohit OP, Tähtelä R, Coleman RE.
    Calcif Tissue Int; 2007 Nov; 81(5):341-51. PubMed ID: 17874331
    [Abstract] [Full Text] [Related]

  • 31. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid.
    Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M, Saad F, Zheng M, Hei YJ, Seaman J, Cook R.
    J Clin Oncol; 2005 Aug 01; 23(22):4925-35. PubMed ID: 15983391
    [Abstract] [Full Text] [Related]

  • 32. Effect of bed rest during pregnancy on bone turnover markers in pregnant and postpartum women.
    Kaji T, Yasui T, Suto M, Mitani R, Morine M, Uemura H, Maeda K, Irahara M.
    Bone; 2007 Apr 01; 40(4):1088-94. PubMed ID: 17229597
    [Abstract] [Full Text] [Related]

  • 33. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G.
    Breast Cancer Res Treat; 2009 Jul 01; 116(1):131-43. PubMed ID: 18668363
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. [Biochemical bone turnover markers in patients with conventional and nonconventional osteosarcoma].
    Ambroszkiewicz J, Gajewska J, Klepacka T, Bilska K, Woźniak W, Laskowska-Klita T.
    Pol Merkur Lekarski; 2006 Oct 01; 21(124):330-4. PubMed ID: 17205770
    [Abstract] [Full Text] [Related]

  • 38. Clinical usefulness of serum pyridinoline cross-linked carboxyterminal telopeptide of type I collagen for diagnosis of bone metastases in patients with primary lung cancer.
    Yokoyama T, Yamamoto M, Shima K, Suzuki K, Sako C, Ito G, Kume M, Maeda M.
    Respirology; 2005 Jun 01; 10(3):300-4. PubMed ID: 15955141
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Bone metabolism markers and ghrelin in boys at different stages of sexual maturity.
    Jürimäe J, Pomerants T, Tillmann V, Jürimäe T.
    Acta Paediatr; 2009 May 01; 98(5):892-6. PubMed ID: 19243352
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.